SOD1 and amyotrophic lateral sclerosis: These results in combination enabled regulatory approval for tofersen to treat patients with SOD1-ALS in the US in 2023.17There is an ongoing study focusing on presymptomatic carriers ofSOD1mutations treated with tofersen and followed in the long term.18